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Bovine immunodeficiency virus (BIV) and Jembrana disease virus (JDV) are closely related bovine lentivi-
ruses that are difficult to distinguish by presently available diagnostic methods. Recently, in our laboratory, a
monoclonal antibody (MAb; MAb 10H1) against the BIV Gag protein identified a differential epitope, located
at the 6.4-kDa N terminus of a 29-kDa Gag capsid protein, which was absent in JDV. To define the essential
amino acids of the epitope, a series of primers within the 163 bp of DNA corresponding to the 6.4-kDa protein
were designed. The full-length 163-bp DNA fragment and the smaller DNA fragments with deletions were
amplified by PCR and then cloned into pQE32 vectors for protein expression studies. The expressed proteins
were analyzed with MAb 10H1 by Western blotting. The differential epitope has been narrowed to a 26-amino-
acid region (R121 to R146), which includes 6 residues of p16MA (where MA represents the matrix protein) and
20 residues of p2L. A synthetic peptide corresponding to the putative 26-amino-acid epitope blocked MAb 10H1
binding to the expressed peptide. These experiments revealed that the epitope spans the cleavage site between
p16MA and p2L and presumably will be valuable in distinguishing the two viruses.
Bovine immunodeficiency virus (BIV) is an RNA lentivirus
of the family Retroviridae. BIV causes lymphadenopathy, lym-
phocytosis, central nervous system lesions, progressive weak-
ness, and associated secondary diseases (8, 18, 21, 24). Al-
though a causal relationship between BIV infections and these
conditions has not been clearly established, BIV infection has
been recognized to result in a high incidence of common dis-
eases that reduce the economic viability of dairy cattle (17).
BIV infection occurs worldwide and has recently been re-
ported in Italy (5) and Australia (3). In Mississippi, the sero-
prevalence of BIV among cattle herds is higher than 50% (19);
however, in western Canada, the prevalence of BIV infection
in cattle is very low (9). Jembrana disease virus (JDV) is also
a lentivirus and is closely related to BIV in terms of its mor-
phogenesis, protein structure, and antigenic reactivity and by
sequence analysis (6, 11). JDV causes an acute and sometimes
fatal disease of domesticated banteng or Bali cattle and is
endemic in parts of Indonesia (23). Both bovine lentiviruses
may be present in Bali cattle populations in some districts (2, 3).
Both BIV and JDV resemble human immunodeficiency vi-
rus (HIV) in their biological, antigenic, and structural proper-
ties. Among the three major structural proteins (encoded by
gag, pol, and env), the Gag protein develops the earliest and
strongest antibodies in infected animals. The BIV Gag precur-
sor (Pr53gag) can be processed into three major proteins (the
matrix [MA], capsid [CA], and nucleocapsid [NC] proteins)
and three smaller proteins (proteins p2L, p3, and p2). The
order of these six proteins in a Gag precursor is NH2-p16
MA-
p2L-p26CA-p3- p13NC-p2-COOH. The proteins have molecu-
lar masses of 14.6, 2.5, 24.6, 2.7, 7.3, and 1.9 kDa, respectively
(20). The strong conservation of Gag epitopes of BIV and HIV
type 1 (HIV-1) has been demonstrated by the serological cross-
reactivity between the two virus capsid proteins. The cross-
reactivity of sera from BIV-infected cattle against JDV recom-
binant capsid protein has been reported (4, 11). The similarity
of the gag genes between BIV and JDV is approximately 62%
at the amino acid level, and the capsid proteins of the two
viruses have a higher degree of amino acid identity (75%).
Serological tests that detect antibody to the capsid protein of
JDV or BIV may not differentiate the two viruses (23).
The BIV gag gene has been cloned, and monoclonal anti-
bodies (MAbs) to recombinant Gag protein have been devel-
oped (22, 25, 26). One of our MAbs, designated 10H1, reacts
specifically with the BIV Gag protein but not with the JDV
Gag protein, indicating that BIV has at least one epitope
different from JDV epitopes. The epitope has already been
located at the 6.4-kDa N terminus of a pATH gag-3 clone (1,
25) which expresses a 29-kDa Gag protein. Detailed knowl-
edge of the epitope would help to elucidate the structural basis
of antigen-antibody recognition to evaluate protein-protein in-
teractions. Identification of antigenic epitopes may also be
important to explore future vaccine strategies (12, 16). The
present study was aimed at defining the makeup of amino acids
required for the unique epitope and elucidating the molecular
mechanisms by which MAb 10H1 differentiates the BIV Gag
protein from the JDV Gag protein.
MATERIALS AND METHODS
gag gene clones and MAb 10H1. A pATH gag-3 clone containing 781 bp of the
gag-coding region from BIV strain R29 was used to generate BIV MAbs, includ-
ing MAb 10H1. The production and characterization of MAb 10H1 were de-
scribed earlier (25). One 751-bp fragment of the gag gene insert was subcloned
into prokaryotic expression vector pQE32, designated pQE32-gag (25, 26), and
was used as a template for PCR amplification of gag gene fragments in this study.
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Construction of expression plasmids. We designed primers with sequences
specific within the 163-bp DNA region corresponding to the 6.4-kDa protein
(25). For cloning of BIV gag fragments into the pQE32 expression vector (QIA-
GEN), the forward primers had BamHI restriction sites at their 5 ends, and the
reverse primers had HindIII sites at their 3 ends. For cloning of the deduced
epitope into the pQE30Xa expression vector (QIAGEN), the forward primer
had an StuI restriction site at the 5 end, and the reverse primer had an HindIII
site at the 3 end. PCR amplification with the primers added the restriction sites
to the ends of the PCR products. The PCR products were cloned into pGEM-T
Easy Vectors by a standard procedure (Promega), and the T vectors were
transformed into Escherichia coli strain JM109. Subsequently, the PCR products
were purified, digested with the corresponding restriction enzymes, and sepa-
rated by electrophoresis on a 1% agarose gel. The BIV gag fragments were
cloned into the pQE32 expression vector at the BamHI-HindIII restriction sites,
and the deduced epitope was cloned into a pQE30Xa expression vector at the
StuI-HindIII restriction sites. The sequences and the reading frames were con-
firmed by the dideoxyribonucleotide chain termination method.
Expression of proteins. E. coli strain M15 was transformed with a pQE32-gag
construct, a pQE30Xa-epitope construct, or a relevant vector alone as a negative
control and was grown at 37°C overnight in 1 ml of Luria-Bertani (LB) broth
containing ampicillin and kanamycin. The cultures were then inoculated with 4
ml of fresh LB broth containing the same antibiotics and were incubated for 30
min at 37°C. Isopropyl--D-thiogalactopyranoside was added to a final concen-
tration of 2 mM to induce protein expression. After 4 h of induction, the cells
were harvested by centrifugation at 3,000  g for 15 min and lysed by heating for
5 min in 500 ml of a 1:1 mixture of phosphate-buffered saline buffer and 2
sample loading buffer (0.125 M Tris, 20% glycerol, 4% sodium dodecyl sulfate,
1% 2-mercaptoethanol).
Western blot assay. The protein samples were loaded onto a discontinuous
Tricine gel (16.5% T, 6% C) (15). Electrophoresis was run at a constant voltage
of 30 V for 1 h and then at 100 V for about 4 h. The proteins were then
transferred onto a nitrocellulose membrane at a constant voltage of 100 V for 1
h with a transblot apparatus. The membrane was blocked with 2% bovine serum
albumin in phosphate-buffered saline containing 0.1% Tween 20 and incubated
with MAb 10H1 at 1:2,000 dilutions at room temperature for 2 h or at 4°C
overnight. Anti-mouse immunoglobulin G peroxidase conjugate (Promega) was
added at 1:3,000, and the mixture was left for 30 min at room temperature.
Specific protein bands were detected with the standard enhanced chemilumines-
cence reagent (Amersham Pharmacia Biotech).
Dot and block blotting. A 6-amino-acid peptide (S-6aa) from the C terminus
of the BIV matrix protein, a 20-amino-acid peptide (S-20aa) from the N-terminal
portion of the p2L protein, and the combined 26-amino-acid peptide (S-26aa)
were synthesized (courtesy of the Biotechnology Core Facility of Kansas State
University). For dot blotting, the peptides were dissolved in distilled water at 0.5
g/ml and the solutions were dotted onto a nitrocellulose membrane. The dotted
membrane was air dried and used to complete the Western blotting as described
above. For block blotting, two synthetic peptides, S-26aa and S-20aa, along with
the proteins expressed from the pQE30Xa-epitope clone were separated by use
of the Tricine gel and transferred onto nitrocellulose membranes. The mem-
branes were prepared and blotted in the same way as described above, except
that MAb 10H1 was preabsorbed with synthetic peptides at a concentration of 1
mg in 20 ml of the blocking buffer for 1 h at room temperature.
RESULTS
Cloning and expression of epitope region. Previously, we
mapped the MAb 10H1-specific epitope by chemical cleavage
analysis and located the differential epitope at the 6.4-kDa N
terminus of the 29-kDa capsid proteins expressed by two dif-
ferent BIV constructs, pATH gag-3 and pQE32-gag (24). To
confirm the result, a pair of primers, primers BIVgag-1F (GG
ATCCAGGCCAGAGCTGATAAGGAA) and BIVgag-1R
(AAGCTTGCTGCTTCATGAGGTCAG), were used to am-
plify the 163-bp fragment corresponding to nucleotides 655 to
817 in a BIV complete proviral genome. The PCR product was
further purified and subcloned into prokaryotic expression vec-
tor pQE32. The 54 amino acids, Gag protein residue R114–
R167, were translated from the vector part with 13 additional
amino acids at the N terminus and 3 amino acids at the C
terminus. The N-terminal 6.4-kDa protein and the 29-kDa BIV
Gag protein were well expressed and reacted positively with
MAb 10H1 in the Western blot, while E. coli strain M15 trans-
formed with vector pQE32 was negative (Fig. 1). This result
verified the location of the MAb 10H1-specific epitope.
Mapping and expression of epitope. To define the epitope
location, we made serial constructs which expressed overlap-
ping peptides. The Gag R114–R146 fragment reacted posi-
tively with MAb 10H1 by Western blotting, the Gag R114–
R145 fragment gave a weak positive reaction, while the Gag
R114–R144 fragment gave a negative response (Fig. 2). These
results indicate that the glutamine at R146 is necessary for the
C terminus in terms of epitope function. Comparison of West-
ern blotting results for the Gag R121–R167 and Gag R122–
R167 fragments demonstrated that the glutamic acid at R121 is
crucial for the N terminus (Fig. 2). The deduced epitope se-
quence covered 26 amino acids from residues R121 to R146.
To verify the sequence, we engineered the corresponding
78-bp DNA fragment into a pQE30Xa expression vector. The
Gag R121–R146 fragment was expressed at a high level in
bacterial strain E. coli M15 and reacted well with MAb 10H1
by Western blotting (Fig. 3, lane 4 of the nonblocking plot).
The results confirmed the mapped position and, therefore,
defined the epitope sequence.
Determination of epitope location. BIV Gag precursor pro-
tein Pr53gag has six proteolytic cleavage products in the order
p16MA, p2L, p26CA, p3, p7MC, and p2 (Fig. 4A). The 54-
amino-acid region (residues R114 to R167) spans three of the
six Gag products: 13 residues at the C terminus of p16MA, 22
residues of p2L, and 19 residues at the N terminus of p26CA
(Fig. 4B). The defined epitope (represented in boldface in Fig.
4B) consists of 6 residues of p16MA and 20 residues of p2L.
The results indicated that the unique epitope excludes the
capsid protein. To further pinpoint the epitope location, we
synthesized S-6aa from p16MA, S-20aa from p2L, and the com-
bination of the peptides (S-26aa). Dot blotting of the three
synthetic peptides demonstrated that only S-26aa gave a pos-
itive reaction with MAb 10H1 (data not shown). Block blotting
was performed to further test the interactions between the
FIG. 1. Expression of the 6.4-kDa N terminus of the BIV Gag
capsid protein (pATH clone). The full-length 29-kDa Gag capsid pro-
tein expressed by the pQE32-gag construct (lane 3) and N-terminal
6.4-kDa protein R114–R167 expressed in vector pQE32 (lane 2) re-
acted positively with MAb 10H1 by Western blotting. E. coli strain
M15 transformed with vector pQE32 (lane 1) was used as the negative
control.
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synthetic peptides and MAb 10H1 (Fig. 3). In the nonblock
plot, S-26aa (Fig. 3, lane 1) and the protein expressed by the
pQE30Xa-epitope clone (Fig. 3, lane 4) reacted with MAb,
while S-20aa (Fig. 3, lane 2) and the negative control (Fig. 3,
lane 3) did not react. The results for the synthetic peptides
were consistent with the dot blotting results. In the 6aa-block
and 20aa-block plots in Fig. 3, S-26aa and the expressed
epitope also reacted positively with MAb 10H1 as strongly as
they did in the nonblock plot. This indicates that neither of the
two synthetic peptides could block the activity of MAb 10H1.
However, in the 26aa-block plot, both S-26aa and the ex-
pressed epitope did not react with MAb 10H1, indicating that
the synthetic epitope completely blocked the activity of the
MAb. The results demonstrate that neither S-6aa of p16MA nor
S-20aa of p2L has the epitope complementarity to block MAb
10H1. Therefore, the epitope must span the cleavage site be-
tween p16MA and p2L.
Differential epitope of BIV from JDV Gag protein. The 26-
amino-acid sequence was aligned against a sequence in the
JDV Gag protein database. The epitope matched a region that
spans the matrix protein and the capsid protein of JDV (Fig.
5). The starting proline for BIV protein p2L matched the
starting proline for the JDV capsid protein. Five of the six
amino acids of the epitope located at the C terminus of the
BIV matrix protein are identical to the corresponding amino
acids of the JDV matrix protein, with high degrees of identity
between the two viruses in the region. Only 3 of the 20 amino
acids in the BIV p2L region match the JDV capsid protein
sequence in the corresponding region, showing the difference
between the two regions. These results indicate that MAb
10H1 does not react with JDV because the p2L region is
missing in JDV.
DISCUSSION
The pATH gag-3 clone contains a 0.8-kb capsid gene from
strain R29 of BIV (1) and was used for the expression of the
BIV capsid protein. We used the clone to generate MAbs
FIG. 2. PCR-based mapping of MAb 10H1-specific epitope. The peptide sequences of Gag fragments in the N-terminal 6.4-kDa protein
(R114–R167) were expressed. The DNA fragments were amplified by PCR, purified from the gel, and cloned into vector pQE32. The vectors were
expressed in E. coli strain M15. Western blotting was done with MAb 10H1. The Western blotting results are designated as follows: , positive;
/, significantly reduced positive; , negative.
FIG. 3. Block blotting of MAb 10H1 by the synthetic epitopes. Lane 1, S-26aa; lane 2, S-20aa; lane 3, E. coli strain M15 transformed with the
pQE30Xa expression vector as a negative control; lane 4, E. coli strain M15 transformed with pQE30Xa engineered with the DNA sequence of
the deduced epitope. The four plots were not blocked (Non-block) or were blocked with S-6aa, S-26aa, and S-20aa, as indicted above each panel.
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including MAb 10H1 (25). The protein of the pATH gag-3
clone expressed in E. coli starts with Gag residue R114, while
the capsid protein starts with residue R149 (20). The MAb
10H1-specific epitope was previously mapped to the N-termi-
nal 6.4-kDa region, which includes 13 residues (R114 to R126)
of p16MA, 22 residues (R127 to R148) of p2L, and 19 residues
(R149 to R167) of p26CA (25). We have now excluded the
epitope from the capsid protein, narrowed the epitope to a
26-amino-acid region, and defined it to the cleavage site span-
ning proteins p16MA and p2L.
Numerous epitopes for HIV have been identified in the
lentiviruses. HIV-1 gag-encoded cytotoxic T-lymphocyte
epitopes, for example, are composed of 7 to 10 amino acids.
The BIV MAb 10H1-specific epitope has been mapped to a
26-amino-acid region and may not be the minimal size for an
epitope. The techniques that we used may not be suitable for
the purpose of fine mapping for two reasons. First, the frag-
ments are too small to be engineered into a construct. Second,
the flanking amino acids from vector parts may interfere with
the reaction between the epitope and the antibody. Our failure
to express the 26-amino-acid epitope in vector pQE32 may be
due to the second problem (data not shown). This suggests that
the epitope could be narrowed to a smaller region around the
cleavage site. Alternatively, the epitope may be affected by the
structure of the 26-amino-acid sequence, which was predicted
to be a helix-turn-helix structure by the Genefold module of
Sybyl (Tripos, St. Louis, Mo.). To resolve this problem, resi-
dues in the middle of the 26-amino-acid sequence should be
mutated to determine their role in antibody specificity. The use
of synthesized peptides is a relatively direct and efficient way
for final mapping of an epitope, but such peptides are expen-
sive. Techniques based on phage display or gene fragment
libraries have been successful for the rapid identification of a
tobacco mosaic virus epitope (7, 10). Perhaps these techniques
could eliminate some of the problems and may help map the
BIV MAb 10H1-specific epitope to a minimal size.
We mapped the epitope to a unique region which spans the
BIV matrix protein and the short protein p2L. Among the
lentiviruses, only the BIV Gag protein contains the intragenic
peptide (p2L) between the matrix and capsid proteins. For
JDV, the p2L short protein was suggested to be incorporated
into the capsid protein (6) or to be absent, as shown in this
study. Only 3 of the 20 amino acids between the BIV p2L
protein and the JDV capsid protein in the corresponding re-
gion are identical. This projects the molecular difference be-
tween BIV and JDV Gag proteins and explains why MAb
10H1 does not react with JDV. Field isolates of BIV contain
p2L, and despite the p2L sequence heterogeneity, the residues
in the cleavage sites are well conserved (20). In general, due to
the molecular difference and the conservation of the cleavage
sites, the MAb 10H1-specific epitope is unique in distinguish-
ing BIV from JDV. This MAb not only reacts specifically with
both the BIV capsid protein and the recombinant fusion pro-
tein (25) but also recognizes BIV-infected bovine lung cells
(Charles Wood, personal communication; data not shown),
suggesting the potential value of MAb 10H1 and the unique
epitope.
FIG. 4. Diagram of the proteolytic products of BIV Pr53gag and the amino acid sequence (R114–R167) in which the MAb 10H1-specific epitope
is located. (A) Proteolytic cleavage products of BIV Gag proteins (Pr53gag). The BIV Gag proteins shown are p16MA, p2L, p26CA, p3, p7MC, and
p2. (B) MAb 10H1-specific amino acid sequence that covers 13 residues (R114 to R126) of p16MA, 22 residues (R127 to R148) of p2L, and 19
residues (R149 to R167) of p26CA. The region in boldface type indicates where the epitope mapped.
FIG. 5. Alignment of the BIV epitope and the JDV Gag protein.
Peptide sequences were aligned by use of the Genetics Computer
Group GAP program. The 26-amino-acid peptide of BIV was aligned
against 255 amino acids of the JDV Gag protein. The corresponding
regions are shown. Both the BIV p2L protein and the JDV capsid
protein start with proline. Vertical lines indicate amino acids that are
identical in the two sequences. MA, matrix protein; CA, capsid pro-
tein.
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JDV is a lentivirus closely related to BIV in terms of its
morphogenesis, protein structure, and antigenic reactivity and
by sequence analysis. Alignment of the gag gene products of
JDV and BIV showed strong overall amino acid identity
(62%), with the matrix protein identity being 60%, the capsid
protein identity being 75%, and the nucleocapsid protein iden-
tity being 63% (6). The high degree of amino acid conservation
explains the difficulty in differentiating the two viruses, either
by biological means or by use of molecular technology. BIV is
widespread, while JDV is restricted to parts of Indonesia. Dis-
tinguishing the two closely related viruses with MAbs will be
important in evaluations of the epidemiology of the disease
and for quarantine purposes. The matrix protein-p2L cleavage
site not only is unique for BIV in relation to JDV but also is
highly conserved, so the unique epitope may be useful for
future study of BIV.
Similar to the results that we have presented for BIV Gag,
MAbs that map to the p17-p24 cleavage site of HIV Gag have
been identified by other investigators, with determinants of
antibody binding found to be located on both p17 and p24 (14).
The MAb was also shown to inhibit cleavage at the p17-p24
site. Another group (13) has shown that MAb to a p17-derived
peptide alone inhibits infection of cells by HIV Gag. Taken
together, the results suggest that MAbs to Gag cleavage sites in
bovine lentiviruses may be further explored for their ability to
interact with and/or inhibit different strains of lentiviruses.
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